PDX Portal

Model Details

Patient Information for Model: BCM-7482

Model Contact

Model: BCM-7482
Model Contact: Michael Lewis
Institution: BCM Breast PDX Program
Email: mtlewis@bcm.edu

Patient Information

Clinical Timeline

Color Keys:

Positive

Negative

N/A

Clinical Information at Collection

Clinical Biomarkers/Mutations at Collection

Pathology Information at Collection

Model Information for Model: BCM-7482

Model Details - Initial Implantation of Patient Tissue

Biomarkers & Mutations

Model Details - Acceptable Conditions for Passaging

Mutations (Cancer Gene Census List)

GeneFilter by Gene	ChrFilter by Chr	Start	End	Ref	Alt	cDNA Change	Codon Change	Protein Change	TVAF	Gene Mutation Freq.	Site Mutation Freq.	Most Severe Effect	All Effects	Mutation Impact	Transcript ID	ClinVar Clinical Significance	COSMIC ID	gnomAD Non-Cancer AF	dbSNP ID	Gene Mutation Freq.	Site Mutation Freq.	Transcript ID	ClinVar Clinical Significance	COSMIC ID	dbSNP ID
AKAP9	chr7	92022864	92022864	A	AAAC	c.4004_4006dup	aaa/aAACaa	p.K1335_L1336insQ	0.931	115	73	In-frame Insertion	In-frame Insertion	MODERATE	ENST00000356239.8		COSV62337888		rs10644111	115	73	ENST00000356239.8		COSV62337888	rs10644111
AKAP9	chr7	92001306	92001306	G	T	c.1389G>T	atG/atT	p.M463I	0.994	115	73	Missense Variant	Missense Variant	MODERATE	ENST00000356239.8	Benign	COSV62345589	0.376835000000	rs6964587	115	73	ENST00000356239.8	Benign	COSV62345589	rs6964587
AKAP9	chr7	92085597	92085597	C	T	c.8935C>T	Cct/Tct	p.P2979S	0.984	115	115	Missense Variant	Missense Variant	MODERATE	ENST00000356239.8	Benign/Likely_benign	COSV104663065	0.996325000000	rs1063242	115	115	ENST00000356239.8	Benign/Likely_benign	COSV104663065	rs1063242
ALK	chr2	29193706	29193706	T	C	c.4381A>G	Atc/Gtc	p.I1461V	0.996	115	115	Missense Variant	Missense Variant	MODERATE	ENST00000389048.8	Benign	COSV101201052	0.997594000000	rs1670283	115	115	ENST00000389048.8	Benign	COSV101201052	rs1670283
ALK	chr2	29193500	29193500	G	C	c.4587C>G	gaC/gaG	p.D1529E	0.476	115	80	Missense Variant	Missense Variant	MODERATE	ENST00000389048.8	Benign	COSV66569695	0.472160000000	rs1881421	115	80	ENST00000389048.8	Benign	COSV66569695	rs1881421
AMER1	chrX	64192810	64192810	A	C	c.477T>G	ttT/ttG	p.F159L	0.535	23	16	Missense Variant	Missense Variant	MODERATE	ENST00000374869.8	Benign	COSV57654201	0.041796500000	rs34677493	23	16	ENST00000374869.8	Benign	COSV57654201	rs34677493
ANK1	chr8	41699515	41699515	C	T	c.2495G>A	cGg/cAg	p.R832Q	0.521	37	2	Missense Variant	Missense Variant	MODERATE	ENST00000289734.13	Conflicting_interpretations_of_pathogenicity	COSV99225084	0.001519360000	rs34523608	37	2	ENST00000289734.13	Conflicting_interpretations_of_pathogenicity	COSV99225084	rs34523608
APC	chr5	112841059	112841059	T	A	c.5465T>A	gTc/gAc	p.V1822D	0.994	100	100	Missense Variant	Missense Variant	MODERATE	ENST00000257430.9	Benign	COSV57321643	0.794920000000	rs459552	100	100	ENST00000257430.9	Benign	COSV57321643	rs459552
AR	chrX	67545316	67545319	TGCA	T	c.237_239del	ctGCAg/ctg	p.Q80del	0.584	101	35	In-frame Deletion	In-frame Deletion	MODERATE	ENST00000374690.9		COSV65954886		.	101	35	ENST00000374690.9		COSV65954886	.
AR	chrX	67545316	67545331	TGCAGCAGCAGCAGCA	T	c.225_239del	ctGCAGCAGCAGCAGCAg/ctg	p.Q76_Q80del	0.381	101	16	In-frame Deletion	In-frame Deletion	MODERATE	ENST00000374690.9		COSV104424802		.	101	16	ENST00000374690.9		COSV104424802	.
ARID1A	chr1	26696761	26696761	C	T	c.358C>T	Ccg/Tcg	p.P120S	0.362	48	2	Missense Variant	Missense Variant	MODERATE	ENST00000324856.13	Conflicting_interpretations_of_pathogenicity	COSV61373973	0.000271628000	rs571264557	48	2	ENST00000324856.13	Conflicting_interpretations_of_pathogenicity	COSV61373973	rs571264557
ARID1B	chr6	157201089	157201089	A	T	c.4864A>T	Atg/Ttg	p.M1622L	0.995	80	4	Missense Variant	Missense Variant	MODERATE	ENST00000636930.2	Benign	COSV51656866	0.003566940000	rs34870395	80	4	ENST00000636930.2	Benign	COSV51656866	rs34870395
ARID2	chr12	45860898	45860898	C	A	c.4871C>A	cCa/cAa	p.P1624Q	0.045	20	1	Missense Variant	Missense Variant	MODERATE	ENST00000334344.11				.	20	1	ENST00000334344.11			.
ASXL1	chr20	32436210	32436210	C	G	c.3498C>G	agC/agG	p.S1166R	0.47	40	2	Missense Variant	Missense Variant	MODERATE	ENST00000375687.10	Benign/Likely_benign	COSV99045599	0.001748830000	rs75887545	40	2	ENST00000375687.10	Benign/Likely_benign	COSV99045599	rs75887545
ASXL2	chr2	25799408	25799408	T	C	c.380A>G	aAa/aGa	p.K127R	0.279	27	10	Missense Variant	Missense Variant	MODERATE	ENST00000435504.9	Benign	COSV55458187	0.048654300000	rs34816614	27	10	ENST00000435504.9	Benign	COSV55458187	rs34816614

CNV

PDX Validation

In order to validate the identity of Baylor College of Medicine patient-derived xenograft (PDX) models, short tandem repeat (STR) testing is performed at the Cytogenetics and Cell Authentication core facility at MDACC. STR testing is performed on tissue from the initial tumor grown in the mouse (transplant generation 1 - TG1) and from a patient sample when possible. Thereafter, STR testing is performed every five transplant generations (TG5, TG10, TG15, and TG20). In the case that a PDX model is transplanted from viably frozen tissue to restart the model, the PDX Core will test the first outgrowth to confirm identity and every five transplant generations thereafter. In addition to STR, we assess clinical biomarkers and histology every 5th transplant generation. Finally, RNAseq gene expression profiles are evaluated periodically to ensure consistency with previous results and to evaluate phenotypic drift. If a significant change in PDX biology is noted, we identify the last known stable stock and re-start the model.

Drug Studies for Model: BCM-7482

Treatment Response Across All Studies

CR <=-95% to -100% PR <-30% to >-95% SD >=-30% to +20% PD >=+20% NA

Drug Study: VFoundation

Study Metadata

Study ID: VFoundation
Study Type: Efficacy
Study Description:
Dosing Initiation Timepoint: Randomization and treatment began after average tumor size in cohort reached 150 mm³
Number of Arms: 10
Mouse Strain:

PI: Mike Lewis
Study Title: VFoundation Study
Treatments: AC, AC+C188-9, C188-9, Carbo, Carbo+C188-9, Doc20, Doc20+C188-9, Pac, Pac+C188-9
Study Duration:
Transplant Site
Transplant Material:

Study Design

Arm Type	Treatment Arms	Number of Mice
Treatment	Docetaxel20+C188-9	6
Treatment	AC	6
Treatment	C188-9	6
Treatment	Docetaxel20	6
Treatment	Carboplatin	6
Treatment	Carboplatin+C188-9	6
Control	Vehicle
Treatment	AC+C188-9	5

Treatment Results

Treatment Arm	Treatment Duration	Monitor Duration	Tumor volume over time (%)	Response Category
Docetaxel20+C188-9	28	273	198	PD
AC	28	273	-81	PR
C188-9	28	273	427	PD
Docetaxel20	28	273	267	PD
Carboplatin	28	273	-87	PR
Carboplatin+C188-9	28	273	-85	PR
Vehicle	28	273	394	PD
AC+C188-9	28	273	-74	PR

Histology Information for Model: BCM-7482

There are no histology images for this model.

Metastasis Information for Model: BCM-7482

Patient

PDX

Abdomen

Adrenal gland

Bone

Bone (de novo)

Bones

Brain

CTC

Chest

Chest wall

Contralateral Breast

Dura

Fallopian Tubes

Head

Kidney

LMD

Liver

Lung

Lymph node

Lymph nodes

Neck

None

Ovary

Pancreas

Pericardium

Peritoneal cavity

Peritoneum

Pleura

Pleural effusion

Shoulder

Skin

Spine

Spleen

Thoracic Spine

Thymus

medistinal and right hilar

Patient Treatment Information for Model: BCM-7482

Event Id	Treatment	Treatment Setting	Age at Start	Age at End	Duration	Clinical Response	Pathologic Response	Reason Stopped
10	Oophorectomy	Prophylactic	51.4	51.4	1 day	Not Reported	Not Applicable	Treatment Completed
25	Docetaxel	Neoadjuvant	52.35	52.52	62 days	Partial Response	Partial Response	Treatment Completed
40	Cyclophosphamide,Doxorubicin	Adjuvant	52.75	52.92	62 days	Not Reported	Not Applicable	Treatment Completed
45	Radiation Therapy	Adjuvant	53.0	53.13	47 days	Not Reported	Not Applicable	Treatment Completed